A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

714

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Esophageal Squamous Cell Carcinoma
Triple Negative Breast Neoplasms
Gastric Cancer
Endometrial Cancer
Pancreatic Adenocarcinoma
Hepatocellular Carcinoma

Interventions

DRUG: PF-08046054
DRUG: pembrolizumab

Sponsor

Seagen, a wholly owned subsidiary of Pfizer